Brief Article
Copyright ©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Sep 7, 2013; 19(33): 5551-5556
Published online Sep 7, 2013. doi: 10.3748/wjg.v19.i33.5551
Effects of extended lymphadenectomy and postoperative chemotherapy on node-negative gastric cancer
Qiang Xue, Xiao-Na Wang, Jing-Yu Deng, Ru-Peng Zhang, Han Liang
Qiang Xue, Xiao-Na Wang, Jing-Yu Deng, Ru-Peng Zhang, Han Liang, Department of Gastric Cancer Surgery, Tianjin Medical University Cancer Hospital and City Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China
Author contributions: Wang XN, Zhang RP and Liang H performed the majority of experiments; Deng JY provided vital reagents and analytical tools and was also involved in editing the manuscript; Xue Q co-ordinated and provided the collection of all the human material in addition to providing financial support for this work; Xue Q designed the study and wrote the manuscript.
Correspondence to: Xiao-Na Wang, PhD, Professor, Department of Gastric Cancer Surgery, Tianjin Medical University Cancer Hospital and City Key Laboratory of Cancer Prevention and Therapy, Lake Road, Hexi District, Tianjin 300060, China. medaction@126.com
Telephone: +86-22-23340123-1061 Fax: +86-22-23559213
Received: May 21, 2013
Revised: June 24, 2013
Accepted: July 18, 2013
Published online: September 7, 2013
Processing time: 110 Days and 13.5 Hours
Core Tip

Core tip: Little information is available regarding the effects of D2 lymphadenectomy and postoperative chemotherapy in patients with node-negative early gastric cancer. Data of 311 gastric cancer patients without lymph node metastasis were analyzed retrospectively. Results showed that D2 lymphadenectomy could improve the survival rate of patients with pT3-stage tumor. However, there was no evidence of a survival benefit from postoperative chemotherapy. In conclusion, it is recommended that D2 lymphadenectomy with gastrectomy be applied for node-negative patients with pT3 gastric cancer whereas the effects of postoperative chemotherapy in patients with node-negative early gastric cancer need to be further studied.